Forest Laboratories Inc. and Glenmark Pharmaceuticals SA Switzerland, a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., announced top-line results from a Phase IIb dose range-finding study of Oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with Oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with
Filed Under:
Pulmonary DiseaseTagged:
Baseline,
Chronic Obstructive Pulmonary Disease,
Daily Show,
Forest Laboratories,
Forest Laboratories Inc,
Glenmark Pharmaceuticals Ltd,
Obstructive Pulmonary Disease,
Phase Iib,
Placebo,
Pulmonary Function,
Subsidiary,
Switzerland,
Trough
Forest Laboratories, Inc . and Glenmark Pharmaceuticals S.A ., a wholly owned subsidiary of Glenmark Pharmaceuticals India today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive ...
http://www.healasthma.com - . (New Jersey) - AEROSOL ASTHMA INHALERS RECALLED A subsidiary of Madison-based Schering-Plough is recalling a batch of asthma inhalers after a complaint from a user who bought one that was empty. Warrick Pharmaceuticals announced Thursday it is voluntarily recalling a single lot of albuterol metered-dose inhaler aerosol g, a prescription medication for the treatment of asthma . The recall affects lot No. -BBS- , which was distributed by Warrick betw
Filed Under:
Lung DiseaseTagged:
Aerosol,
Albuterol,
Asthma,
Asthma Inhalers,
Bbs,
Betw,
Dose Inhaler,
Medication,
Prescription Medication,
Schering Plough,
Subsidiary,
Treatment Of Asthma,
Vanceril,
Warrick Pharmaceuticals
